Last reviewed · How we verify

NCT03737331: VISNA

Variable Visual Stimulus as a Novel Approach for Gait Rehabilitation

Terminated NA Last updated 3 September 2024
What this trial tests

NA trial testing Fractal visual cueing in Gait Disorders, Neurologic in 1 participant. Terminated before completion.

Timeline
9 November 2018
Primary endpoint
15 July 2019
15 July 2019

Quick facts

Lead sponsorUniversity of Nebraska
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment1
Start date9 November 2018
Primary completion15 July 2019
Estimated completion15 July 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Nebraska

Who can join

Adults 65 to 90, any sex, with Gait Disorders, Neurologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Deterioration in walking performance as a result of disease or simply as a result of aging is a serious threat to independence in older adults. In this project, the investigators propose an innovative visual stimulus, based on advanced mathematical and biological theories, with which older adults can walk in time to improve their walking. The investigators' goal is to apply this simple, cost-effective, and novel gait rehabilitation therapy across all populations who have difficulties walking, e.g. stroke patients, fallers or those who undergo joint replacement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gait Disorders, Neurologic

Currently open trials in the same condition.

Other University of Nebraska trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing